Tecartus Suspension
Product Images NDC 71287-219

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tecartus (NDC 71287-219). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Kite Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (68 mL Bag Label)

Label for TECARTUS brexucabtagene autoleucel, a cellular therapy intravenous suspension. The label includes dosage and content details for one sterile infusion bag containing up to 2 x 10^8 autologous anti-CD19 CAR T cells in 68 mL suspension with 5% DMSO, manufactured by Kite Pharma, Inc. It specifies storage in vapor phase liquid nitrogen at or below -150°C and warnings against leukodepleting filters and irradiation.*

FDA Label Image

Principal Display Panel (68 mL Cassette Label)

Label for TECARTUS brexucabtagene autoleucel suspension for intravenous use, NDC 71287-219-02. The label specifies it is for autologous and intravenous use only, with no U.S. standard of potency. It includes instructions for contents: up to 2 x 10^8 autologous anti-CD19 CAR T cells in approximately 68 mL suspension with 5% DMSO USP. Manufacturer is Kite Pharma, Inc., Santa Monica, CA.*

FDA Label Image

Principal Display Panel (68 mL Bag Label)

Label for TECARTUS (brexucabtagene autoleucel), a cellular therapy suspension for intravenous use by Kite Pharma, Inc. The label includes patient verification instructions, a lot number, patient and hospital IDs, and an expiration date.*

FDA Label Image

Principal Display Panel (68 mL Cassette Label)

Label for TECARTUS (brexucabtagene autoleucel) cellular therapy suspension for intravenous infusion by Kite Pharma, Inc. The label includes a prominent red stop sign instructing to confirm patient ID prior to infusion, patient identification fields including lot number, patient IDs, expiration date, patient name, date of birth, and barcodes.*

FDA Label Image

Principal Display Panel (68 mL LN2 Label)

Label for TECARTUS (brexucabtagene autoleucel) cellular therapy suspension by Kite Pharma, Inc. The label shows the product name, manufacturer, cell order number, lot number, and an address in Santa Monica, CA. The label includes two barcodes associated with the cell order and lot number.*

FDA Label Image

Brexucabtagene 06

Label for TECARTUS brexucabtagene autoleucel cellular therapy suspension for intravenous use. The label specifies a dose of one sterile bag containing up to 1 x 10^8 autologous anti-CD19 CAR T cells in approximately 68 mL with 5% DMSO USP. It includes handling instructions such as gentle mixing while thawing, storage in vapor phase of liquid nitrogen at ≤-150°C, and warnings not to use a leukodepleting filter or to irradiate. Manufactured by Kite Pharma, Inc., Santa Monica, CA.*

FDA Label Image

Brexucabtagene 07

The label for TECARTUS brexucabtagene autoleucel, a cellular therapy suspension for intravenous use. It states the dosage form as one sterile bag for infusion with about 1 x 10^8 anti-CD19 CAR T cells in 68 mL suspension containing 5% DMSO. Instructions highlight careful thawing and storage at temperatures ≤ -150°C. Manufactured by Kite Pharma, Inc., with contact details provided.*

FDA Label Image

Brexucabtagene 08

Label for TECARTUS (brexucabtagene autoleucel) cellular therapy suspension for intravenous use. The label includes patient verification information such as lot number, patient ID, expiration date, patient name initials, date of birth, hospital patient ID, and a barcode with DIN number. The labeler is Kite Pharma, Inc.*

FDA Label Image

Brexucabtagene 09

Label for TECARTUS (brexucabtagene autoleucel) cellular therapy suspension for intravenous use, showing patient verification instructions including a bold red stop sign to confirm patient ID prior to infusion. It includes patient identifiers such as lot number, Kite patient ID, expiration date, patient name, date of birth, hospital patient ID, and a barcode with a DIN number. The labeler is Kite Pharma, Inc.*

FDA Label Image

Brexucabtagene 10

Label for TECARTUS (brexucabtagene autoleucel) cellular therapy from Kite Pharma, Inc. The label includes the product and manufacturer name, barcode images, a cell order number, a lot number, and the manufacturer's address in Santa Monica, California.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.